Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivian A Fonseca

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
Clinical Cornerstone|March 25, 2008
Identification and treatment of prediabetes to prevent progression to type 2 diabetesVivian A Fonseca
Diabetes Care|October 31, 2009
Defining and characterizing the progression of type 2 diabetesVivian A Fonseca
The American Journal of Cardiology|September 6, 2003
Management of diabetes mellitus and insulin resistance in patients with cardiovascular diseaseVivian A Fonseca
Current Medical Research and Opinion|January 14, 2010
Effects of beta-blockers on glucose and lipid metabolismVivian A Fonseca
The American Journal of Medicine|May 26, 2009
Demystifying incretin therapy for type 2 diabetes. IntroductionVivian A Fonseca
Clinical Cornerstone|May 5, 2009
Identification and treatment of prediabetes to prevent progression to type 2 diabetesVivian A Fonseca
European Journal of Internal Medicine|July 8, 2009
Demystifying incretin therapy for type 2 diabetes. IntroductionVivian A Fonseca
The American Journal of Medicine|September 14, 2007
Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitusVivian A Fonseca
Clinical Cornerstone|March 25, 2008
Insulin therapy in type 2 diabetes. IntroductionVivian A Fonseca
The American Journal of Medicine|January 4, 2011
Exploring the spectrum of incretin therapies: the potential for optimizing patient outcomes. IntroductionVivian A Fonseca
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
Clinical Cornerstone|March 25, 2008
Identification and treatment of prediabetes to prevent progression to type 2 diabetesVivian A Fonseca
Diabetes Care|October 31, 2009
Defining and characterizing the progression of type 2 diabetesVivian A Fonseca
The American Journal of Cardiology|September 6, 2003
Management of diabetes mellitus and insulin resistance in patients with cardiovascular diseaseVivian A Fonseca
Current Medical Research and Opinion|January 14, 2010
Effects of beta-blockers on glucose and lipid metabolismVivian A Fonseca
The American Journal of Medicine|May 26, 2009
Demystifying incretin therapy for type 2 diabetes. IntroductionVivian A Fonseca
Clinical Cornerstone|May 5, 2009
Identification and treatment of prediabetes to prevent progression to type 2 diabetesVivian A Fonseca
European Journal of Internal Medicine|July 8, 2009
Demystifying incretin therapy for type 2 diabetes. IntroductionVivian A Fonseca
The American Journal of Medicine|September 14, 2007
Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitusVivian A Fonseca
Clinical Cornerstone|March 25, 2008
Insulin therapy in type 2 diabetes. IntroductionVivian A Fonseca
The American Journal of Medicine|January 4, 2011
Exploring the spectrum of incretin therapies: the potential for optimizing patient outcomes. IntroductionVivian A Fonseca
Pageof 19